Overview

* Edesa Biotech Inc ( EDSA ) Q3 loss per share narrows to $0.25 from $0.52 last year; net loss remains $1.7 mln

* Loss from operations stable at $1.9 mln

Result Drivers

* EB06 FOCUS - Increased expenditures on EB06 for vitiligo study offset by reduced EB05 expenses, supported by government funding

* EXPENSE MANAGEMENT - Stable operating expenses reflect strategic resource allocation towards EB06 development

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.25

Q3 Net -$1.7

Income mln

Q3 loss $1.9 mln

from

operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Edesa Biotech Inc ( EDSA ) is $9.00, about 76.8% above its August 7 closing price of $2.09

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)